TP53 mutation can elicit oncogenic activities besides the loss of tumor suppression function [36], previous studies have explored the predictive role of TP53 in NSCLC with chemotherapy treatment, but the results were inconsistent. The gene discussed is TP53; the disease is neoplasm.